UC loses patent battle over prostate cancer drug in SA

The University of California's (UC) patent for Xtandi, a prostate cancer drug, was revoked in South Africa, allowing generic alternatives to enter the market.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here

Tagged Astellas Pharma, Drug Pricing, Enzalutamide, Oncology, Patent Law, Prostate Cancer, South Africa Generic Drugs, UC, Xtandi